181 related articles for article (PubMed ID: 16545395)
1. Heart failure reduces both the effects and interaction between cyclic GMP and cyclic AMP.
Moalem J; Weiss HR; Davidov T; Rodriguez R; Molino B; Lazar MJ; Scholz PM
J Surg Res; 2006 Aug; 134(2):300-6. PubMed ID: 16545395
[TBL] [Abstract][Full Text] [Related]
2. Pacing-induced cardiac failure of hypertrophic hearts: effects of cyclic GMP reduction.
Huang MW; Weiss HR; Tse J; Leone RJ; Scholz PM
J Surg Res; 1999 Sep; 86(1):89-96. PubMed ID: 10452873
[TBL] [Abstract][Full Text] [Related]
3. Cyclic GMP and cyclic AMP induced changes in control and hypertrophic cardiac myocyte function interact through cyclic GMP affected cyclic-AMP phosphodiesterases.
Weiss HR; Gong GX; Straznicka M; Yan L; Tse J; Scholz PM
Can J Physiol Pharmacol; 1999 Jun; 77(6):422-31. PubMed ID: 10537228
[TBL] [Abstract][Full Text] [Related]
4. The effect of intracoronary nitroprusside on cyclic GMP and regional mechanics is altered in a canine model of left ventricular hypertrophy.
Roitstein A; Kedem J; Cheinberg B; Weiss HR; Tse J; Scholz PM
J Surg Res; 1994 Nov; 57(5):584-90. PubMed ID: 7967596
[TBL] [Abstract][Full Text] [Related]
5. Negative metabolic and coronary flow effects of decreases in cAMP and increases in cGMP in control and renal hypertensive rabbit hearts.
Rodriguez R; Molino B; Weiss HR; Scholz PM
J Appl Physiol (1985); 2004 Jul; 97(1):439-45. PubMed ID: 14990553
[TBL] [Abstract][Full Text] [Related]
6. Cyclic GMP attenuates cyclic AMP-stimulated inotropy and oxygen consumption in control and hypertrophic hearts.
Leone RJ; Straznicka M; Scholz PM; Weiss HR
Basic Res Cardiol; 2000 Feb; 95(1):28-38. PubMed ID: 10752543
[TBL] [Abstract][Full Text] [Related]
7. Positive functional effects of milrinone and methylene blue are not additive in control and hypertrophic canine hearts.
Leone RJ; Weiss HR; Scholz PM
J Surg Res; 1998 Jun; 77(1):23-8. PubMed ID: 9698527
[TBL] [Abstract][Full Text] [Related]
8. Altered effects of acetylcholine on cyclic AMP and GMP induced changes in O2 consumption of hypertrophic dog cardiac myocytes.
Gong GX; Straznicka M; Weiss HR; Tse J; Scholz PM
J Auton Pharmacol; 1999 Feb; 19(1):19-28. PubMed ID: 10385266
[TBL] [Abstract][Full Text] [Related]
9. Positive inotropy due to lowering cyclic GMP is also mediated by increases in cyclic AMP in control and hypertrophic hearts.
Naim KL; Rabindranauth P; Weiss HR; Tse J; Leone RJ; Scholz PM
Can J Physiol Pharmacol; 1998 Jun; 76(6):605-12. PubMed ID: 9923398
[TBL] [Abstract][Full Text] [Related]
10. Action of acetylcholine on regional myocardial work and metabolism in vivo: association with cyclic GMP.
Guo X; Kedem J; Scholz PM; Weiss HR
Can J Physiol Pharmacol; 1996 Jan; 74(1):73-9. PubMed ID: 8963954
[TBL] [Abstract][Full Text] [Related]
11. Effects of coronary vasodilator on cyclic nucleotides. The concentrations of cyclic AMP and cyclic GMP in canine coronary artery and left ventricular muscle following the administration of various coronary vasodilators.
Kobayashi A; Ogawa K
Jpn Circ J; 1979 Dec; 43 Suppl 1():6-8, 46-54. PubMed ID: 230369
[TBL] [Abstract][Full Text] [Related]
12. Effect of isoproterenol on coronary blood flow and signal transduction responses in thyroxine-treated rabbit hearts.
Rodriguez E; Weiss HR; Gonzalez M; Tse J
J Mol Cell Cardiol; 1993 Aug; 25(8):939-47. PubMed ID: 8263963
[TBL] [Abstract][Full Text] [Related]
13. Interaction between the opposing functional effects of cyclic AMP and cyclic GMP in hypertrophic cardiac myocytes.
Patel KN; Yan L; Gandhi A; Scholz PM; Weiss HR
Basic Res Cardiol; 2001 Feb; 96(1):34-41. PubMed ID: 11215530
[TBL] [Abstract][Full Text] [Related]
14. Importance of ryanodine receptors in effects of cyclic GMP is reduced in thyroxine-induced cardiac hypertrophy.
Zhang Q; Goel N; Rodriguez R; Scholz PM; Weiss HR
Eur J Pharmacol; 2006 May; 537(1-3):45-51. PubMed ID: 16626695
[TBL] [Abstract][Full Text] [Related]
15. Negative inotropic effects of C-type natriuretic peptide are attenuated in hypertrophied ventricular myocytes associated with reduced cyclic GMP production.
Moalem J; Davidov T; Zhang Q; Grover GJ; Weiss HR; Scholz PM
J Surg Res; 2006 Sep; 135(1):38-44. PubMed ID: 16600302
[TBL] [Abstract][Full Text] [Related]
16. Cyclic GMP reduces myocardial stunning through non-cyclic GMP protein kinase mechanisms.
Zhang Q; Lazar M; Yan L; He Y; Tse J; Weiss HR; Scholz PM
J Cardiovasc Pharmacol; 2004 Aug; 44(2):235-43. PubMed ID: 15243306
[TBL] [Abstract][Full Text] [Related]
17. Cyclic GMP but not cyclic AMP prevents renal platelet accumulation after ischemia-reperfusion in anesthetized rats.
Chintala MS; Bernardino V; Chiu PJ
J Pharmacol Exp Ther; 1994 Dec; 271(3):1203-8. PubMed ID: 7996427
[TBL] [Abstract][Full Text] [Related]
18. T4-induced cardiac hypertrophy disrupts cyclic GMP mediated responses to brain natriuretic peptide in rabbit myocardium.
Katz E; Zhang Q; Weiss HR; Scholz PM
Peptides; 2006 Sep; 27(9):2276-83. PubMed ID: 16762459
[TBL] [Abstract][Full Text] [Related]
19. Myocardial effects of cyclic AMP phosphodiesterase inhibition are dampened in thyroxine-induced cardiac hypertrophy.
Straznicka M; Leone RJ; Scholz PM; Weiss HR
J Surg Res; 1998 Apr; 76(1):61-6. PubMed ID: 9695741
[TBL] [Abstract][Full Text] [Related]
20. Milrinone, a cyclic AMP-phosphodiesterase inhibitor, has differential effects on regional myocardial work and oxygen consumption in experimental left ventricular hypertrophy.
Chiu WC; Kedem J; Weiss HR; Tse J; Cheinberg BV; Scholz PM
Cardiovasc Res; 1994 Sep; 28(9):1360-5. PubMed ID: 7954646
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
